This bill amends the Full-Year Continuing Appropriations and Extensions Act, 2025, to significantly increase funding for Defense Health Agency (DHA) research, development, test, and evaluation (RDT&E) . It specifically raises the appropriation amount in Section 1407(1) of Public Law 119-4 by over $1 billion, from $40,395,072,000 to $41,576,684,000, with this change taking effect retroactively. A key provision ensures that funds allocated for Congressionally Directed Medical Research Programs (CDMRP) are implemented in a manner consistent with the Consolidated Appropriations Act, 2024. The Secretary of Defense is mandated to use these funds to support all research programs and initiatives identified in the explanatory statement accompanying the 2024 Act. This measure aims to preserve program continuity and adhere to specified funding allocations and research priorities for vital medical research.
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Appropriations.
Sponsor introductory remarks on measure. (CR E561)
Introduced in House
Referred to the House Committee on Appropriations.
Sponsor introductory remarks on measure. (CR E561)
Armed Forces and National Security
Medical Research for Our Troops Act
USA119th CongressHR-3906| House
| Updated: 6/11/2025
This bill amends the Full-Year Continuing Appropriations and Extensions Act, 2025, to significantly increase funding for Defense Health Agency (DHA) research, development, test, and evaluation (RDT&E) . It specifically raises the appropriation amount in Section 1407(1) of Public Law 119-4 by over $1 billion, from $40,395,072,000 to $41,576,684,000, with this change taking effect retroactively. A key provision ensures that funds allocated for Congressionally Directed Medical Research Programs (CDMRP) are implemented in a manner consistent with the Consolidated Appropriations Act, 2024. The Secretary of Defense is mandated to use these funds to support all research programs and initiatives identified in the explanatory statement accompanying the 2024 Act. This measure aims to preserve program continuity and adhere to specified funding allocations and research priorities for vital medical research.